000274213 001__ 274213
000274213 005__ 20240229154929.0
000274213 0247_ $$2doi$$a10.3390/jcm12051892
000274213 0247_ $$2pmid$$apmid:36902678
000274213 037__ $$aDKFZ-2023-00499
000274213 041__ $$aEnglish
000274213 082__ $$a610
000274213 1001_ $$aWang, Zhaohui$$b0
000274213 245__ $$aClinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer.
000274213 260__ $$aBasel$$bMDPI$$c2023
000274213 3367_ $$2DRIVER$$aarticle
000274213 3367_ $$2DataCite$$aOutput Types/Journal article
000274213 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1678868528_29494
000274213 3367_ $$2BibTeX$$aARTICLE
000274213 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274213 3367_ $$00$$2EndNote$$aJournal Article
000274213 520__ $$aCancer immunotherapy plays a crucial role in bladder cancer (BC) progression. Increasing evidence has elucidated the clinicopathologic significance of the tumor microenvironment (TME) in predicting outcomes and therapeutic efficacy. This study sought to establish a comprehensive analysis of the immune-gene signature combined with TME to assist in BC prognosis. We selected sixteen immune-related genes (IRGs) after a weighted gene co-expression network and survival analysis. Enrichment analysis revealed that these IRGs were actively involved in Mitophagy and Renin secretion pathways. After multivariable COX analysis, the IRGPI comprising NCAM1, CNTN1, PTGIS, ADRB3, and ANLN was established to predict the overall survival of BC, which was validated in both TCGA and GSE13507 cohorts. In addition, a TME gene signature was developed for molecular and prognosis subtyping with unsupervised clustering, followed by a panoramic landscape characterization of BC. In summary, the IRGPI model developed in our study provided a valuable tool with an improved prognosis for BC.
000274213 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000274213 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274213 650_7 $$2Other$$abiomarker
000274213 650_7 $$2Other$$abladder cancer
000274213 650_7 $$2Other$$aimmune-related genes
000274213 650_7 $$2Other$$aprognosis
000274213 650_7 $$2Other$$atumor microenvironment
000274213 7001_ $$aWang, Tao$$b1
000274213 7001_ $$aWu, Gangfeng$$b2
000274213 7001_ $$0P:(DE-He78)0116f5652cc0dbf455e3aa3914740230$$aZhu, Lei$$b3$$udkfz
000274213 7001_ $$aZhang, Jian$$b4
000274213 773__ $$0PERI:(DE-600)2662592-1$$a10.3390/jcm12051892$$gVol. 12, no. 5, p. 1892 -$$n5$$p1892$$tJournal of Clinical Medicine$$v12$$x2077-0383$$y2023
000274213 909CO $$ooai:inrepo02.dkfz.de:274213$$pVDB
000274213 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0116f5652cc0dbf455e3aa3914740230$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000274213 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000274213 9141_ $$y2023
000274213 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-09-04T08:13:34Z
000274213 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-17
000274213 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-17
000274213 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-17
000274213 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-17
000274213 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN MED : 2022$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:59:21Z
000274213 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:59:21Z
000274213 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:59:21Z
000274213 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000274213 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000274213 9201_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x0
000274213 980__ $$ajournal
000274213 980__ $$aVDB
000274213 980__ $$aI:(DE-He78)A430-20160331
000274213 980__ $$aUNRESTRICTED